The Efficacy and Safety of Nirsevimab in the Prevention of RSV Related Infections in Healthy Infants
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Date of Graduation
12-13-2024
Semester of Graduation
Fall
Abstract
Objective: To assess the efficacy and safety of preventing Respiratory Syncytial virus (RSV) related respiratory illnesses and hospitalization with the use of Nirsevimab, as compared to placebo among infants among healthy early and late preterm infants less than one year of age. Design: Systematic Literature Review
Methods: Searches were done using Pubmed and the search term Nirsevimab in Fall 2023. Records were excluded from analysis if full text was not available, studies other than randomized control trials or if included infants that were not healthy or born before 29 weeks gestation. Results: Of the 3 studies, 2 studies demonstrated reduction of lower respiratory tract infections (LRTI) and hospitalizations due to RSVin the Nirsevimab group compared to placebo. All 3 studies showed decreased adverse events in the Nirsevimab injection group compared to the placebo group. All results were statistically significant. Conclusion: Nirsevimab administration reduces the incidence of RSV related LRTI and hospitalizations and demonstrates a good safety profile for the use in healthy infants.
Recommended Citation
Ballard S, Mayo G. The Efficacy and Safety of Nirsevimab in the Prevention of RSV Related Infections in Healthy Infants. 2023.
